Related Experiment Video
Updated: Aug 7, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children
Salvador Resino1, Rosa Resino, José Maria Bellón
1Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain. sresino.hgugm@salud.madrid.org
Insights
Highly active antiretroviral therapy (HAART) significantly reduced AIDS cases, deaths, and hospitalizations in vertically HIV-1 infected children. This effective treatment protocol improved CD4 counts and viral load, enhancing overall clinical outcomes.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Public Health
Background:
- Antiretroviral therapy (ART) has improved outcomes for children with human immunodeficiency virus type 1 (HIV-1).
- Effectiveness of different ART protocols on clinical outcomes in children requires ongoing evaluation.
- Vertical HIV-1 transmission poses significant health challenges in pediatric populations.
Purpose of the Study:
- To evaluate the effectiveness of various antiretroviral therapy protocols on clinical outcomes in vertically HIV-1 infected children.
- To assess changes in CD4(+) cell counts, viral load, and adverse clinical events over distinct treatment eras.
Main Methods:
- Retrospective study of 427 vertically HIV-1 infected children.
- Follow-up divided into five calendar periods (CPs) reflecting evolving ART strategies (pre-ART, monotherapy, combination therapy, partial HAART, full HAART).
- Analysis of clinical outcomes including AIDS incidence, mortality, hospital admissions, and hospitalization duration.
Main Results:
- Significant improvements in CD4(+) cell count and viral load observed from 1997 onwards with HAART.
- CP5 (1999-2003), with >60% HAART use, showed significantly lower AIDS cases (2%) and deaths (0.5%) compared to earlier periods.
- HAART era (CP4 & CP5) demonstrated >3.5 relative risk for no hospital admission and reduced hospitalization duration.
Conclusions:
- Highly active antiretroviral therapy (HAART) is highly effective in reducing adverse clinical outcomes in vertically HIV-1 infected children.
- Transition to HAART protocols led to substantial decreases in AIDS incidence, mortality, and hospitalizations.
- Findings support the critical role of HAART in managing pediatric HIV-1 infection, as demonstrated in Madrid, Spain.
Abstract:
Background. Use of antiretroviral therapy has resulted in a decrease in morbidity and mortality rates in human immunodeficiency virus type 1 (HIV-1)-infected children.Methods. We performed a retrospective study involving 427 children to determine the effectiveness of different antiretroviral therapy protocols on clinical outcome. The follow-up period was divided into 5 calendar periods (CPs): CP1 (1980-1989), before antiretroviral therapy was administered; CP2 (1990-1993), when monotherapy was administered; CP3 (1994-1996), when combined therapy was administered; CP4 (1997-1998), when =50% of children were receiving highly active antiretroviral therapy (HAART); and CP5 (1999-2003), when >/=60% of children were receiving HAART.Results. Children experienced a progressive increase in the CD4(+) cell count and decrease in the viral load from 1997 onwards. A lower number of AIDS cases and deaths occurred during CP5 than during the other CPs (P<.01), with a relative risk of an absence of AIDS of >20 and a relative risk of survival of >30. The AIDS rate was >50% in CP1; we observed a very strong decrease to 14% in CP2, to 16% in CP3, to 7% in CP4, and to 2% in CP5. The mortality rates in CP2 and CP3 were >6% and thereafter decreased to 0.5% in CP5. The relative risks for no hospital admission in CP4 and CP5 were >3.5. The total rates of hospital admission in CP1, CP2, and CP3 were >30%; we observed a decrease in CP4 and CP5. The duration of hospitalization decreased during the follow-up period, and it was higher in CP1 (~30 days) than in the other periods.Conclusions. We observed that HAART produces a decrease in adverse clinical outcomes (i.e., hospital admission, AIDS, and death) in children with vertical HIV-1 infection in Madrid, Spain.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Cryptococcal Meningitis
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Inhibitors of Virion Maturation and Assembly
